Posaconazole-induced hypertension in children with cystic fibrosis

Respirol Case Rep. 2021 Aug 4;9(9):e0822. doi: 10.1002/rcr2.822. eCollection 2021 Sep.

ABSTRACT

Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF). Rarely, posaconazole can cause pseudohyperaldosteronism, manifesting as hypertension and electrolyte abnormalities, with a number of cases recently reported in individuals without CF. We describe two cases of children with CF who developed hypertension, likely due to pseudohyperaldosteronism, following the initiation of posaconazole for the treatment of ABPA.

PMID:34377495 | PMC:PMC8334806 | DOI:10.1002/rcr2.822

Source: Industry